Hoffmann-la Roche Inc.

The Scripps Research Institute

Ptc Therapeutics, Inc.

F. Hoffmann-la Roche Ag

Ptc Theranentics. Inc.

Luke Green

Patrizio Mattei

Johannes Aebi

Hasane Ratni

Synese Jolidon

Hans Peter Maerki

Alfred Binggeli

Guido Hartmann

Georg Jaeschke

Heinz Stadler

Wolfgang Guba

Olivier Roche

Emmanuel Pinard

Peter Mohr

Eric Vieira

Fabienne Ricklin

Lothar Lindemann

Nikolai A Naryshkin

Marla L Weetall

K Barry Sharpless

Valery Fokin

Fahmi Himo

Antonio Ricci

Daniel Rueher

Gary Mitchell Karp

Hongyan Qi

Jana Narasimhan

Amal Dakka

Matthew G Woll

Ellen Welch

Soongyu Choi

Xiaoyan Zhang

Nanjing Zhang

Xin Zhao

Tianle Yang

Vsevold A Rostovtsev

Anthony A Turpoff

Vsevold V Rostovtsev

Andrew William Thomas

Henner Knust

Rainer Eugen Martin

Anja Limberg

Thomas Luebbers

Jean-Michel Adam

Karlheinz Baumann

Alexander Flohr

Erwin Goetschi

Haiyan Wang

Peter Zahm

Anthony A Yurpoff

Nicole Risher

Patrick Williamson

Andreas D Christ

The present invention provides compounds of formula (I)

Compounds for treating spinal muscular atrophy

Provided herein are compounds of Formula (I): and forms thereof, wherein w, w, w, w, w, wand ware as defined herein, including compositions thereof and uses therewith for treating spinal muscular atrophy.

The present invention provides compounds of formula (I) 

Provided herein are compounds of Formula (I): 

The present invention provides compounds of formula (I) wherein A, B, X, Y, R1 and R2 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments. 

Substituted imidazo[1,2-&#x3b1;]pyrazines for treating spinal muscular atrophy

Provided herein are compounds of Formula (I): and forms thereof, including compositions thereof and uses therewith for treating spinal muscular atrophy.

The invention provides compounds having the general formula I wherein n, R, R, R, Rand Rare as herein defined, composition comprising the compounds and methods of using the compounds.

Oxazolidinone and imidazolidinone compounds

The present invention relates to ethynyl compounds of formula I-C1 whereinR, R, R, R, R, R, U, V and W are as defined herein and to a pharmaceutically acceptable acid addition salts, to a racemic mixtures, or to its corresponding enantiomers and/or optical isomers and/or stereoisomers thereof, which are allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5).

Arlethynyl derivatives

A copper catalyzed click chemistry ligation process is employed to bind azides and terminal acetylenes to provide 1,4-disubstituted 1,2,3-triazole triazoles. The process comprises contacting a solution of an organic azide and a terminal alkyne with a source of catalytic Cu(I) ion to form a 1,4-disubstituted 1,2,3-triazole, wherein the source of Cu(I) ion comprises Cu(II) and a metal capable of reducing Cu(II) to Cu(I). In some embodiments, the metal capable of reducing Cu(II) to Cu(I) is selected from the group consisting of Al, Be, Co, Cr, Fe, Mg, Mn, Ni, and Zn.

Copper-catalysed ligation of azides and acetylenes

A copper catalyzed click chemistry ligation process is employed to bind azides and terminal acetylenes to provide 1,4-disubstituted 1,2,3-triazole triazoles. The process comprises contacting an organic azide and a terminal alkyne with a source of reactive Cu(I) ion in human blood plasma to form by cycloaddition a 1,4-disubstituted 1,2,3-triazole. The source of reactive Cu(I) ion can be, for example, a Cu(I) salt, Cu(II) ion in the presence of a reducing agent, or copper metal.

The present invention relates to ethynyl compounds of formula wherein X, Y, Z, and Rare as defined hereinor to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. Compounds of formula I are positive allosteric modulators (PAM) of the metabotropic glutamate receptor subtype 5 (mGluR5) and they are therefore useful for the treatment of diseases related to this receptor.

Ethynyl compounds useful for treatment of CNS disorder

Growing community of inventors

Basel, Switzerland

Luke Green